Total cell-free DNA measurement in metastatic colorectal cancer with a fast and easy direct fluorescent assay.
biomarker
cell-free DNA
colorectal adenocarcinoma
metastatic colorectal cancer
systemic therapy
Journal
Molecular and clinical oncology
ISSN: 2049-9469
Titre abrégé: Mol Clin Oncol
Pays: England
ID NLM: 101613422
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
received:
23
08
2021
accepted:
27
10
2021
entrez:
14
2
2022
pubmed:
15
2
2022
medline:
15
2
2022
Statut:
ppublish
Résumé
Treatment for metastatic colorectal cancer (mCRC) is focused on prolonging survival and maintaining quality of life. It is important to establish prognostic and predictive markers to avoid extended, ineffective treatment. The aim of the present study was, by a novel approach, to analyze the association between cell-free (cf)DNA levels and outcome in patients receiving systemic therapy for incurable mCRC. The study was a prospective non-interventional biomarker study for patients receiving standard of systemic treatment for mCRC. Patients with mCRC, who, according to standard guidelines, were considered for treatment with EGFR inhibitors, were included. The cfDNA levels in consecutive plasma samples were measured by a direct fluorescence assay. The study included 47 patients. Blood samples were available at baseline (n=47); prior to the third treatment cycle (n=31); the first (n=33), second (n=22) and third response evaluation during treatment (n=17); and at progression (n=22). The disease control rate was 42 and 91% in patients with high (≥75
Identifiants
pubmed: 35154704
doi: 10.3892/mco.2022.2497
pii: MCO-16-3-02497
pmc: PMC8822899
doi:
Banques de données
ClinicalTrials.gov
['NCT03750175']
Types de publication
Journal Article
Langues
eng
Pagination
64Informations de copyright
Copyright © 2020, Spandidos Publications.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Int J Cancer. 2014 Dec 15;135(12):2984-91
pubmed: 24798213
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Int J Cancer. 2014 Nov 1;135(9):2215-22
pubmed: 24659028
Ann Clin Biochem. 2009 Nov;46(Pt 6):488-94
pubmed: 19729503
C R Seances Soc Biol Fil. 1948 Feb;142(3-4):241-3
pubmed: 18875018
Clin Cancer Res. 2012 Feb 15;18(4):1177-85
pubmed: 22228631
Br J Cancer. 2014 Jan 21;110(2):363-8
pubmed: 24231948
Ann Oncol. 2019 Jul 1;30(7):1088-1095
pubmed: 31046124
Mol Clin Oncol. 2020 Dec;13(6):77
pubmed: 33005411
Eur J Cancer. 2015 Nov;51(17):2678-85
pubmed: 26508156
Cancer Res. 1977 Mar;37(3):646-50
pubmed: 837366
Oncol Lett. 2018 Aug;16(2):2654-2660
pubmed: 30013661
Clin Exp Metastasis. 2015 Jun;32(5):457-65
pubmed: 25899064
Ann Oncol. 2014 Sep;25 Suppl 3:iii1-9
pubmed: 25190710
Radiother Oncol. 2020 Sep;150:211-216
pubmed: 32622778
Tumour Biol. 2018 Nov;40(11):1010428318811207
pubmed: 30486767
Eur J Cancer. 2005 Aug;41(12):1690-6
pubmed: 16043346
Clin Chim Acta. 2015 Jun 15;446:141-6
pubmed: 25896958
Oncology. 1989;46(5):318-22
pubmed: 2779946
Ther Adv Med Oncol. 2020 May 26;12:1758835920918472
pubmed: 32518596
Oncologist. 2017 Sep;22(9):1049-1055
pubmed: 28778958
Clin Chim Acta. 2018 Dec;487:107-111
pubmed: 30240586
Ann Oncol. 2018 Mar 1;29(3):610-615
pubmed: 29253083
PLoS One. 2015 Apr 13;10(4):e0108247
pubmed: 25875772
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593